Condition: Breast Cancer · Sponsor: The Netherlands Cancer Institute
This study evaluates the acute toxicity and feasibility of repeat breast conserving therapy with preoperative accelerated partial breast re-irradiation (PAPBI) in female patients aged 51 years or older with ipsilateral recurrent or second primary low-risk breast cancer or DCIS.
This description comes directly from the study's public registry record.
Tess Snellen, MD · 0205129111 · t.snellen@nki.nl
Lisa van den Hengel · 0205129111 · l.vd.hengel@nki.nl
Always discuss trial participation with your own doctor first.
| The Netherlands Cancer Institute | Amsterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06362616